Song Shubin, Sun Luhao, Liu Xiaoyu, Zhang Liang, Li Chao, Liu Zhaoyun, Liu Fengzhen, Yu Zhiyong
Department of Breast Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, People's Republic of China.
Department of Breast and Thyroid Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, People's Republic of China.
Breast Cancer (Dove Med Press). 2025 Jul 24;17:669-681. doi: 10.2147/BCTT.S523199. eCollection 2025.
This study aimed to analyze factors affecting the prognosis of patients with hormone receptor-positive (HR+) and human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) treated with palbociclib and endocrine therapy (ET).
Patients with HR+/HER2- MBC who were treated with palbociclib plus ET between January 2019 and December 2020 at Shandong Cancer Hospital were recruited. Clinicopathological data, treatment outcomes, and survival were from electronic medical system and telephone follow-up.
A total of 90 eligible patients were recruited in this study; 55 (61.11%) patients preferred chemotherapy as first treatment, and 35 (38.89%) preferred ET as first treatment. The percentages for 1st, 2nd line, and ≥3 lines applying palbociclib were 17.78%, 16.66%, and 65.56%, respectively. In the univariate analysis, multiple factors influenced the primary overall survival (pOS, from initial diagnosis of BC to death), progression-free survival (PFS), and mOS (from diagnosis of metastasis to death). Meanwhile in the multivariate analysis, pPR (progesterone receptor of primary tumor) and prior ET response were independent risk factors for pOS, PFS, and mOS. Lower pPR and prior ET resistance predicted poorer pOS, PFS, and mOS in HR+/HER2- MBC patients. Number of lines of palbociclib application was an independent risk factor for pOS and mOS and presented higher points both in the pOS and mOS nomograms, meaning that palbociclib had a more significant impact on pOS and mOS compared to other factors. The nomograms showed excellent discrimination and prediction accuracy with area under curves (AUC) of 0.974 for pOS, 0.627 for PFS, and 0.881 for mOS, respectively.
This real-world single-center study of patients with HR+/HER2- MBC showed that early application of palbociclib combined with ET may bring better PFS, but not pOS and mOS. pPR and prior ET response were independent risk factors affecting prognosis.
本研究旨在分析影响接受哌柏西利和内分泌治疗（ET）的激素受体阳性（HR+）和人表皮生长因子2阴性（HER2-）转移性乳腺癌（MBC）患者预后的因素。
招募2019年1月至2020年12月期间在山东省肿瘤医院接受哌柏西利联合ET治疗的HR+/HER2-MBC患者。临床病理数据、治疗结果和生存情况来自电子医疗系统和电话随访。
本研究共招募了90例符合条件的患者；55例（6
